Esperion Therapeutics Inc. plans to offer $150 million of its common stock in an underwritten public offering, subject to market and other conditions.

The company intends to grant the underwriters an option to buy up to an additional $22.5 million of common stock.

Jefferies LLC, Cowen and UBS Investment Bank are acting as joint book-running managers for the proposed offering.